ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies has seen its share price move sharply in recent years, and the question now is whether the cash flows the business can generate really back up that kind of ride. With the stock recently closing at US$29.57 and investor attention drawn to new clinical guideline support for its testing platform, the focus turns to what the current valuation says about its future cash streams. Over the past 3 years the stock has returned about 432.8%, which puts a lot of weight on the...

Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company’s clonoSEQ assay. Investors have reacted quickly to the guideline update, with Adaptive Biotechnologies’ share price up 6.02% over the past day and posting a 12.65% 30-day share price return, while the 1-year total shareholder return of 125.21% and 3-year total shareholder...

Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-cleared clonoSEQ assay with preferred high-sensitivity thresholds and expanded testing timepoints. The inclusion of clonoSEQ by name, alongside broader recommendations for routine and longitudinal MRD assessment, strengthens its position as a standardized tool...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoSEQ and expand testing time points to include annual assessments during maintenance and testing after later treatment lines. The update strengthens the case for monitoring minimal residual disease, or […]

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging from $17 to $30. Investor focus has shifted from ADPT’s technology to its business execution, with technical indicators and momentum...

Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation

Investors are watching Adaptive Biotechnologies (ADPT) after forecasts pointed to a reduced quarterly loss of $0.13 per share and 12.6% revenue growth for the June 2026 quarter, alongside its track record of beating earnings estimates. See our latest analysis for Adaptive Biotechnologies. At a share price of $22.31, Adaptive Biotechnologies has seen strong recent momentum, including a 29.48% 1 month share price return and a 57.78% 3 month share price return, while the 1 year total shareholder...

Adaptive Biotechnologies stock has delivered very strong total returns over the past three years, while its valuation signals are pulling in different directions, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting upside and market based multiples pointing to a richer price. Shareholders have seen a 185.3% total return over three years, which puts extra focus on whether the current price still leaves room for further upside. Expectations for future revenue growth in...

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earlier this week, Adaptive Biotechnologies was upgraded to a Zacks Rank #2 (Buy) following upward revisions to its earnings estimates and expectations for a smaller quarterly loss alongside higher revenue for the June 2026 quarter. This shift in analyst expectations suggests confidence that the company’s underlying business trends are improving, supported by a recent pattern of earnings estimate beats. Now we’ll examine how this upward revision in earnings expectations may influence...

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.